Appointed Chief Scientific Officer effective January 2, 2024, having joined the board as a Class I director in September 2022 (resigning from the board effective January 1, 2024). Professor and Alvera L. Kan Endowed Chair of Neurological Surgery and Radiation Oncology at UCSF with 30+ years in gene therapy.